News
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Berlin Cures' BC 007 Targets Long COVID: Solid Phase II Trial Progress with Over 50% Patient Recruitment
Berlin Cures reaches over 50% patient recruitment in Phase II trial for Long COVID treatment with BC 007, aiming to neutralize harmful autoantibodies. CEO emphasizes global impact and urgent need for innovative solutions -
COMMUNIQUÉ DE PRESSE
Berlin Cures takes next step in battle against Long COVID
-
COMMUNIQUÉ DE PRESSE
Berlin Cures starts Long COVID Phase II Trial – first patients admitted